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Introduction: Soluble urokinase-type plasminogen activator (suPAR) represents a marker for immune activation
and has predictive value in critically ill patients. The kinetics of suPAR and its correlation with the immune
response and outcome in trauma patients are unknown.
Methods: Plasma concentrations of inﬂammatory cytokines and suPAR were determined in adult trauma patient
(n = 69) samples obtained by the Helicopter Emergency Medical Services at arrival at the emergency depart-
ment (ED) and at days 1, 3, 5, 7, 10, and 14.
Results: Initial suPAR levels were unrelated to injury severity score and higher in nonsurvivors compared with
survivors, although no differencewas observed between early and latemortality. The area under the receiver op-
erating characteristic curve to predict mortality was 0.6 (95% conﬁdence interval, 0.48-0.72). Soluble urokinase-
type plasminogen activator levels increased over time in 94% of patients, although suPAR increase did not pre-
cede death. Tumor necrosis factor α at the ED correlated with suPAR at that time point, whereas concentrations
of other proinﬂammatory cytokines at the ED correlated with suPAR levels at days 1 and 5.
Conclusions: After trauma, initial suPAR plasma concentrations are higher in nonsurvivors compared with survi-
vors, but its predictive value is low. Soluble urokinase-type plasminogen activator levels increase over time after
trauma, and concentrations at later time points are related to cytokine levels at the ED.
© 2015 Elsevier Inc. All rights reserved.1. Introduction
Trauma is one of themain causes of death worldwide. In 2000, 9% of
deaths and 12% of disease burden could be attributed to trauma. More-
over, 50% of trauma-related deaths concern young people between the
ages of 15 and 44 years [1]. Roughly, trauma deaths can be divided
into early deaths attributable to the direct effect of trauma, such as
blood loss or neurologic damage and late mortality, to an important ex-
tent due to immunological complications [2,3]. Trauma can result in a
systemic inﬂammatory response, predominantly induced by the release
of danger-associated molecular patterns [4]. These “danger signals” canrest.
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.pickkers@radboudumc.nleither be components from ruptured cells and tissues or factors released
by cells in stressed conditions [4]. Pattern recognition receptors, which
recognize pathogen-associated molecular patterns, can be triggered by
danger-associated molecular patterns. Although the exact mechanisms
are not completely elucidated yet, this can lead to proinﬂammatory re-
sponses as well as a refractory state of the immune system called
“immunoparalysis,”which renders patients vulnerable toward secondary
infections [5]. Apart from injury severity scores, no predictors ofmortality
are available for this important patient group.
Soluble urokinase-type plasminogen activator receptor (suPAR) is a
recently identiﬁed biomarker for inﬂammation in infectious diseases
that is superior in predicting outcome in various conditions compared
with other markers [6,7]. Soluble urokinase-type plasminogen activator
receptor particularly appears to be of value in combination with other
biomarkers [6,8]. The nonsoluble formof suPAR, urokinase plasminogen
activator receptor (or CD87), is expressed on immune cells, for example,
neutrophils, monocytes, macrophages, and lymphocytes [9], and does
play a role in ﬁbrinolytic pathways [10,11]. Plasma levels of suPAR are
increased in various infectious and inﬂammatory diseases [12-14].
Moreover, several observational studies demonstrate the relation
Table 1
Patient characteristics
Sex Male: n = 48 (69.6%)
Female: n = 21 (30.4%)
Age, median (range) 50 (18-95)
Length of stay in days, median (range) 9 (0-201)
28-d survival n = 50 (72.5%)
ISS, median (range) 29 (3-66)
Head/neck injury (ISS region 1) n = 53, 80.3%
Face injury (ISS region 2) n = 17, 25.8%
Chest injury (ISS region 3) n = 42, 63.3%
Abdomen or pelvic contents injury (ISS region 4) n = 24, 36.4%
Extremities or pelvic girdle injury (ISS region 5) n = 40, 60.6%
External injury (ISS region 6) n = 31, 47.0%
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[8,15,16]. However, suPAR levels in trauma patients and their relation
with outcome have not been investigated.
Considering the importance of the immune response in latemortality
of trauma patients and the high prognostic value of suPAR in inﬂamma-
tory conditions, the objective of this study was to investigate the prog-
nostic value (for both early and late mortalities) of plasma suPAR levels
in trauma patients and to study the relationwithmarkers of systemic in-
ﬂammation and injury severity in this speciﬁc group of patients.2. Materials and methods
2.1. Study population
Adult trauma patients (n = 69) admitted to the trauma care unit at
the emergency department (ED) of the Radboud University Nijmegen
Medical Center, a level I trauma center, were included in the study.
Exclusion criteria were expected clinical risks of blood sampling,
known HIV/AIDS, known malignancies, and use of steroids or other
immunomodulating medication. Two healthy male volunteers (aged
20 and 25 years) were used as healthy controls.
The study has been carried out in the Netherlands in accordance
with the applicable rules concerning the review of research ethics com-
mittees and informed consent. All patients or legal representativeswere
informed about the study details at the ﬁrst opportunity, usually at day
1 after admission. The local ethical committee that approved the study
protocol agreed that it was not possible to do this at an earlier stage.
Written informed consent was obtained if venapuncture was necessary
to obtain blood samples. Informed consent was waived in case blood
could be sampled from existing arterial or venous catheters. All experi-
ments were performed under the guidelines of The National InstitutesFig. 1. Soluble urokinase-type plasminogen activator levels after trauma. A, Plasma suPAR levels
activator levels increased over time (P b .0001) according to 1-way analysis of variance andwere
to Bonferroni multiple comparison post hoc test. Data are expressed as mean± SEM. Median age
controls. B, Regression coefﬁcients were generally positive (n = 33; mean ± SEM, 0.38 ± 0.05)of Health and in accordance with the declaration of Helsinki and its
later amendments.2.2. Sample collection
Bloodwas sampled shortly after trauma by theHelicopter Emergency
Medical Services (HEMS) at arrival at the ED and at days 1, 3, 5, 7, 10, and
14 after trauma. EDTA-anticoagulated blood was centrifuged after with-
drawal at 1600g at 4°C for 10 minutes, after which plasma was stored
at−80°C until further analysis.2.3. Sample analysis
Plasma concentrations of suPARwere analyzed in 1 batch by enzyme-
linked immunosorbent assay (detection limits, 1.1-22.5 ng/mL)
according to the manufacturer's instructions (SuPARnostic;
Virogate A/S, Birkerød, Denmark). Plasma concentrations of tumor ne-
crosis factor (TNF) α, interleukin (IL) 6, IL-10, IL-8, interferon (IFN) γ,
and monocyte chemoattractant protein (MCP) 1 were analyzed by a
Luminex assay according to the manufacturer's instructions (Milliplex;
Millipore, Billerica, MA). Clinical parameters and demographic data
were obtained from electronic patient ﬁles. Injury Severity Score (ISS)
and Abbreviated Injury Scale were supplied by the Regional Emergency
Healthcare Network.2.4. Statistical analysis
Data are expressed as mean ± SEM or median (interquartile range
[IQR]), according to their distribution as determined using the
Kolmogorov-Smirnov test. Statistical tests used are indicated in the ﬁgure/
table legends or text. All analyses were performed with available
data of the corresponding time points. Because of missing values at
certain time points or patients that were lost to follow-up, patient
numbers in the various analysesmight not correspondwith the original
inclusion number.
Linear regression coefﬁcients were calculated from patients that
had a follow-up of 3 or more days (n = 33) to quantify suPAR kinetics
over time.
A receiver operating characteristic curve according to DeLong et al,
[30] sensitivity, speciﬁcity, positive predictive value, and negative pre-
dictive value were calculated using MedCalc version 11.3.1.0 (MedCalc
software, Ostend, Belgium).
Other statistical analyses were performed using Graphpad Prism 5
software (Graphpad Software, La Jolla, CA). P b .05 was considered
statistically signiﬁcant.were measured at 8 different time points after trauma. Soluble urokinase-type plasminogen
signiﬁcantly higher than values of healthy controls (indicated in gray/dotted line) according
per time point is displayed in years. ⁎P b .05, ⁎⁎P b .01, ⁎⁎⁎P b .001 compared with healthy
, indicating increasing suPAR concentrations over time.
Fig. 2. Soluble urokinase-type plasminogen activator and survival. A, Initial plasma suPAR levels (determined at HEMS or ED) were signiﬁcantly lower in survivors in comparison with
nonsurvivorswho diedwithin 5 days after trauma. No differences in suPAR levelswere observed between early and latemortalities. Data are expressed asmean± SEM. ⁎P b .05 according
to 1-way analysis of variancewith Bonferronimultiple comparison post hoc test. B, Regression coefﬁcientswere similar in survivors and nonsurvivors according to unpaired Student t test.
C, Plasma suPAR concentrations in nonsurvivors. Day 0 indicates day of death; days−7 to−1 represent the days preceding death. No increase in suPAR preceding death was observed.
There were no statistically signiﬁcant differences between time points according to 1-way analysis of variance.
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3.1. Patient characteristics
A total of 69 patientswere included, ofwhich themajority had head/
neck injury and/or chest injury. Of 69 patients, 3 had penetrating injury.
Patient characteristics are shown in Table 1.3.2. Plasma suPAR concentrations after trauma
Mean plasma suPAR level at time point HEMS was 3.2 ± 0.4 ng/mL
and signiﬁcantly increased over time (Fig. 1A), further illustrated
by positive regression coefﬁcients in 94% of patients with a mini-
mum follow-up of 3 days (mean regression coefﬁcient of 0.4 ±
0.1 ng/mL per day; Fig. 1B). Furthermore, mean plasma suPAR levels
in patients were signiﬁcantly different from mean suPAR levels
found in healthy controls (2.7 ng/mL) from time point ED onwards
(Fig. 1A). The concentrations that we found in samples from healthy
controls were similar to those found in healthy controls in previous
studies [17-19].
Therewas no correlation (r=0.12; P=.38) between suPAR and ISS.
A weak but statistically signiﬁcant correlation was found between age
and suPAR (r= 0.29; P= .02).Fig. 3. Receiver operating characteristic curve suPAR. Receiver operating characteristic
curve analysis showing the utility of ﬁrst plasma suPAR concentration as a prognostic
test predicting death in trauma patients. The area under the curve was 0.60 (95%
CI, 0.48-0.72).3.3. Relation between suPAR levels and early and late mortalities
Initial suPAR levels (ﬁrst sample of a patient, obtained at time point
HEMS, ED, or day 1) were higher in nonsurvivors (n = 22; 4.1 ±
0.5 ng/mL) compared with survivors (n= 45; 3.0 ± 0.2 ng/mL; P= .02).
Furthermore, patients who died early (within 5 days) as well as those
who died later (after 6 or more days) demonstrated higher suPAR levels
in comparison with survivors (Fig. 2A), although this difference was
only signiﬁcant between the survival and early mortality groups. No
statistically signiﬁcant difference in suPAR levels between the early
and late mortality groups was observed.
There was no difference in the increase in suPAR concentration be-
tween survivors and nonsurvivors, as regression coefﬁcients between
were similar (Fig. 2B). Finally, no differences were observed in suPAR
levels shortly before patients died, indicating that death itself is not pre-
ceded by an increase in suPAR (Fig. 2C).3.4. Predictive value of early suPAR
A receiver operating characteristic (ROC) curve was produced using
the ﬁrst obtained suPAR value to evaluate its predictive value for mor-
tality (Fig. 3). The area under the curve was 0.60 (95% conﬁdence inter-
val [CI], 0.48-0.72). The optimal cutoff point (N3.66 pg/mL) resulted in a
sensitivity of 50% (95% CI, 28.2-71.8), speciﬁcity of 76.6% (95% CI, 62.0-
87.7), positive predictive value of 50% (95% CI, 28.2-71.8), and negative
predictive value of 76.6% (95% CI, 62.0-87.7).
3.5. Relation between cytokines at ED and suPAR levels
Median plasma cytokine levels at ED were IFN-γ of 3 pg/mL (IQR, 3-
3), IL-10 of 45 pg/mL (IQR, 20-206), IL-6 of 25 pg/mL (IQR, 8-68), IL-8 of
11pg/mL (IQR, 7-26),MCP-1 of 422pg/mL (IQR, 269-806), and TNF-α of
6 pg/mL (IQR, 3-12). According to Pearson correlation test after log
transformation of cytokine values, plasma suPAR levels at time point
ED correlated with plasma TNF-α measured at the same time point
(r=0.43; P b .01), whereas no correlation between other plasma cyto-
kines and suPAR levels at time point ED was found. However, proin-
ﬂammatory cytokines IL-6, IL-8, and MCP-1 measured at the ED did
correlate with suPAR levels at days 1, 3, and/or 5 (Table 2).
Table 2
Correlation between cytokine levels at the ED and suPAR levels at various time points
ED suPAR Day 1 suPAR Day 3 suPAR Day 5 suPAR
ED TNF-α R= 0.43, P b .01, n = 51 R= 0.08, P= .60, n = 38 R=−0.02, P= .89, n = 23 R= 0.12, P= .60, n = 19
ED IL-6 R= 0.20, P= .15, n = 51 R= 0.17, P= .28, n = 38 R= 0.46, P= .02, n = 23 R= 0.47, P= .04, n = 19
ED IL-8 R= 0.18, P= .20, n = 51 R= 0.32, P= .04, n = 38 R= 0.48, P= .01, n = 23 R= 0.51, P= .02, n = 19
ED IL-10 R= 0.03, P= .81, n = 51 R= 0.11, P= .49, n = 38 R= 0.21, P= .33, n = 23 R= 0.26, P= .28, n = 19
ED MCP-1 R=−0.03, P= .82, n = 51 R= 0.22, P= .17, n = 38 R= 0.41, P= .05, n = 23 R= 0.46, P= .04, n = 19
ED IFN-γ R=−0.01, P= .95, n = 47 R= 0.06, P= .71, n = 34 R=−0.20, P= .37, n = 21 R= 0.10, P= .69, n = 16
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Herein, we show that plasma suPAR levels increase over time in
trauma patients. Moreover, this study is the ﬁrst to demonstrate that
suPAR levels shortly after trauma are higher in nonsurvivors than in sur-
vivors, although predictive value for mortality was low and death itself
was not preceded by an increase in suPAR. Furthermore, early increases
in proinﬂammatory cytokine levels are related to increased suPAR levels
at later time points.
Several studies have demonstrated that suPAR is not as valuable as a
single marker in clinical practice, mainly because of the lack of a clear
cutoff value. Studies in (suspected) sepsis patients demonstrated ROC
curves with an area under the curve between 0.5 and 0.75, and thus,
the value of suPAR in triage is unclear [6,8]. This is in accordance with
our results, as we demonstrate that the value of plasma suPAR concen-
tration as a triagemarker in individual patients is limited and its positive
and negative predictive values are low. It is suggested that, in sepsis or
in patients with suspected infection at the ED, suPAR could be of value
when combined with other biomarkers, which could also hold true for
trauma patients [6,8].
Of interest, we demonstrated a relation between early cytokine pro-
duction and subsequent increase of suPAR levels. Patients with an initial
high cytokine response had high plasma suPAR concentrations later on
during their hospital stay. This ﬁndingmay indicate that the increase of
suPAR over time could be mediated by the initial inﬂammatory re-
sponse in trauma patients, although we cannot demonstrate causality
from our data set. In accordance, previous in vitro studies have demon-
strated that neutrophils can release suPAR in response to stimulation
with IL-8 or TNF-α [20] and endothelial cells after stimulation with IL-
1β or PDGF. [21] Although the exact mechanism behind suPAR release
has not yet been elucidated completely [22], based on these and our re-
sults, it seems possible that cytokines play a role in this process. Never-
theless, the mediator responsible for the increased plasma suPAR
concentration directly after trauma is unclear. Cytokines are unlikely
to play a role in this initial increase, regarding the lack of correlation be-
tween cytokine levels and plasma suPAR at the ED. Moreover, in our pa-
tient cohort, relatively low plasma cytokine concentrations were found
comparedwith other conditions, such as sepsis [23]. This might explain
the relatively mildly increased suPAR levels (mean, 4.1 ng/mL) in trau-
ma patients at admission compared with those observed in patients
with sepsis (median, 8.9 [range, 5.9-12.7] ng/mL) [24].
Our study has several limitations. Inherent to this kind of study, the
number of patients that can be analyzed over time is limited as a sub-
stantial number of patients were lost to follow-up, for example, because
of death, transfer to another hospital, or withdrawal from the study.
However, the increase in suPAR over time does not appear to result
from the lost-to follow up, as the regression coefﬁcients were positive
in virtually all patients with a follow-up of at least 3 days. Moreover,
the increasing trend in suPAR is also observed in the subgroup of pa-
tients that had a complete follow-up. Therefore, it appears unlikely
that the increase in suPAR is the result of exclusion of less severely ill pa-
tients or patients who die during follow-up. Another weakness of the
current study is the heterogeneity of the patients, which is inherent to
the trauma patient population studied. Age could possibly have con-
founded our results. Various studies have assessed the relation between
age and suPAR in several diseases, with contradictory results. Somedemonstrate no correlation [25,26], whereas others demonstrate higher
[27,28] or lower [29] suPAR levels in elderly patients. We found a weak
but statistically signiﬁcant correlation between age and suPAR. We do
not think that that the increased suPAR levels in trauma patients are
the result of the higher age of the patient cohort, also because suPAR
levels increased over time in our cohort, while median age did not.
5. Conclusions
In conclusion, early suPAR concentrations are higher in nonsurvivors
than in survivors, and levels at later time points are related to preceding
cytokine levels. However, the predictive value of suPAR for mortality
and, therefore, its clinical relevance is low. The steady increase over
time related to the initial inﬂammatory response is not related
to mortality.
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